26 Analysts Assess Gilead Sciences: What You Need To Know
Daiwa Securities Adjusts Gilead Sciences Price Target to $90 From $73
Gilead Sciences Is Maintained at Sector Perform by RBC Capital
Gilead Sciences Analyst Ratings
Express News | Gilead : RBC Raises Target Price to $84 From $81
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.